PMID- 28480621
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20181202
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 24
IP  - 6
DP  - 2017 Jun
TI  - Efficacy and safety of pramipexole extended-release in Parkinson's disease: a 
      review based on meta-analysis of randomized controlled trials.
PG  - 835-843
LID - 10.1111/ene.13303 [doi]
AB  - BACKGROUND AND PURPOSE: We performed a meta-analysis of randomized controlled 
      trials to evaluate the efficacy and safety of pramipexole extended-release 
      (pramipexole ER) versus pramipexole immediate-release (pramipexole IR) or placebo 
      in Parkinson's disease. METHODS: We performed a systematic online search for 
      clinical trials for pramipexole ER treatment up to 1 August 2016. We assessed 
      differences in Unified Parkinson's Disease Rating Scale (UPDRS) scores, 
      percentage of 'on' time or 'off' time, withdrawals, adverse events (AEs) and life 
      quality between pramipexole ER and pramipexole IR or placebo. Data analyses were 
      performed by the Cochrane Collaboration's Review Manager 5.3 software. RESULTS: 
      Six randomized controlled trials were included. Compared with placebo, 
      pramipexole ER achieved a significant improvement in the UPDRS Part II + III 
      score [weighted mean difference, -4.81; 95% confidence interval (CI), -6.40 to 
      -3.23], whereas no significant difference was found in the UPDRS Part III + III 
      score between pramipexole ER and pramipexole IR groups (weighted mean difference, 
      -0.26; 95% CI, -1.15 to 0.64). No differences were found in total AEs (relative 
      risk, 0.97; 95% CI, 0.92 to 1.03), drug-related AEs (relative risk, 0.97; 95% CI, 
      0.92 to 1.03) or the commonly reported AEs between pramipexole ER and pramipexole 
      IR. CONCLUSIONS: Pramipexole ER is as safe and effective as pramipexole IR in the 
      treatment of Parkinson's disease.
CI  - (c) 2017 EAN.
FAU - Shen, T
AU  - Shen T
AD  - Department of Neurology, Second Affiliated Hospital of Medical School of Zhejiang 
      University, Hangzhou City, Zhejiang, China.
FAU - Ye, R
AU  - Ye R
AD  - Department of Neurology, Second Affiliated Hospital of Medical School of Zhejiang 
      University, Hangzhou City, Zhejiang, China.
FAU - Zhang, B
AU  - Zhang B
AD  - Department of Neurology, Second Affiliated Hospital of Medical School of Zhejiang 
      University, Hangzhou City, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170508
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Benzothiazoles)
RN  - 0 (Delayed-Action Preparations)
RN  - 83619PEU5T (Pramipexole)
SB  - IM
MH  - Antiparkinson Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Benzothiazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations/administration & dosage/adverse effects/therapeutic 
      use
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Mental Status and Dementia Tests
MH  - Parkinson Disease/diagnosis/*drug therapy
MH  - Pramipexole
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Parkinson's disease
OT  - efficacy
OT  - meta-analysis
OT  - pramipexole extended-release
OT  - safety
EDAT- 2017/05/10 06:00
MHDA- 2018/02/13 06:00
CRDT- 2017/05/09 06:00
PHST- 2016/10/03 00:00 [received]
PHST- 2017/03/21 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
PHST- 2017/05/09 06:00 [entrez]
AID - 10.1111/ene.13303 [doi]
PST - ppublish
SO  - Eur J Neurol. 2017 Jun;24(6):835-843. doi: 10.1111/ene.13303. Epub 2017 May 8.